Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.com 

Moderna generates one-tenth of Bristol Myers Squibb's revenue, making their nearly equal valuations hard to justify. x.com 

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Moderna's cash burn and persistent operating losses make profitable commercialization the central constraint despite promising melanoma results. Its revenue remains too small and uneven to cover development costs, while rising diluted shares weaken financial resilience. x.com 

Moderna's customer options positioning was not bullish, and the stock subsequently flushed 20%. WizOfOps described the top 10 trades as only modestly bearish, with no solid consensus among the customers dominating the flow. x.com 

Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com 

Moderna is a stock to bet against. x.com 

Moderna faces about 67% downside to the Wall Street analyst price target of $50.84 per share. x.com  x.com 

Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com